FGF23 Antibody - #DF3596

(3)   (6)  
Product: FGF23 Antibody
Catalog: DF3596
Description: Rabbit polyclonal antibody to FGF23
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Horse, Dog
Mol.Wt.: 27 KD; 28kD(Calculated).
Uniprot: Q9GZV9
RRID: AB_2835968

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
IF/ICC 1:100-1:500, WB 1:500-1000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Horse(91%), Dog(100%)
Clonality:
Polyclonal
Specificity:
FGF23 Antibody detects endogenous levels of total FGF23.
RRID:
AB_2835968
Cite Format: Affinity Biosciences Cat# DF3596, RRID:AB_2835968.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ADHR; FGF-23; Fgf23; FGF23_HUMAN; FGFN; Fibroblast growth factor 23; Fibroblast growth factor 23 C-terminal peptide; Fibroblast growth factor 23 precursor; HPDR2; HYPF; Phosphatonin; PHPTC; Tumor derived hypophosphatemia inducing factor; Tumor-derived hypophosphatemia-inducing factor;

Immunogens

Immunogen:
Uniprot:

Q9GZV9(FGF23_HUMAN) >>Visit HPA database.

Gene(ID):
FGF23(8074)
Expression:
Q9GZV9 FGF23_HUMAN:

Expressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts).

Sequence:
MLGARLRLWVCALCSVCSMSVLRAYPNASPLLGSSWGGLIHLYTATARNSYHLQIHKNGHVDGAPHQTIYSALMIRSEDAGFVVITGVMSRRYLCMDFRGNIFGSHYFDPENCRFQHQTLENGYDVYHSPQYHFLVSLGRAKRAFLPGMNPPPYSQFLSRRNEIPLIHFNTPIPRRHTRSAEDDSERDPLNVLKPRARMTPAPASCSQELPSAEDNSPMASDPLGVVRGGRVNTHAGGTGPEGCRPFAKFI

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Dog
100
Horse
91
Rabbit
73
Pig
0
Bovine
0
Sheep
0
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q9GZV9 As Substrate

Site PTM Type Enzyme
Y51 Phosphorylation
Y70 Phosphorylation
S71 Phosphorylation
Y154 Phosphorylation
S155 Phosphorylation
S159 Phosphorylation
T178 O-Glycosylation
S180 Phosphorylation Q8IXL6 (FAM20C)
S207 Phosphorylation
S212 Phosphorylation

Research Backgrounds

Function:

Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL (By similarity). Acts directly on the parathyroid to decrease PTH secretion (By similarity). Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization.

PTMs:

Following secretion this protein is inactivated by cleavage into a N-terminal fragment and a C-terminal fragment. The processing is effected by proprotein convertases.

O-glycosylated by GALT3. Glycosylation is necessary for secretion; it blocks processing by proprotein convertases when the O-glycan is alpha 2,6-sialylated. Competition between proprotein convertase cleavage and block of cleavage by O-glycosylation determines the level of secreted active FGF23.

Subcellular Location:

Secreted.
Note: Secretion is dependent on O-glycosylation.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts).

Subunit Structure:

Interacts with FGFR1, FGFR2, FGFR3 and FGFR4. Affinity between fibroblast growth factors (FGFs) and their receptors is increased by KL and heparan sulfate glycosaminoglycans that function as coreceptors (By similarity).

Family&Domains:

Belongs to the heparin-binding growth factors family.

Research Fields

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

References

1). Osteoporotic bone recovery by a bamboo-structured bioceramic with controlled release of hydroxyapatite nanoparticles. Bioactive Materials, 2022 (PubMed: 35386445) [IF=18.9]

Application: WB    Species: Rat    Sample:

Fig. 3 Effect of nwHA bioceramics on cocultured osteoporotic osteoblasts. (A) First line: CLSM observations of live (green)/dead (red) staining of osteoporotic osteoblasts cocultured with different nwHA (first line); Second line: CLSM observations of the osteoporotic osteoblasts with F-actin stained with Phalloidin-TRITC (red) and nuclei stained with DAPI (blue). (B) Cell viability of osteoporotic osteoblasts cocultured with different nwHA bioceramics at days 1, 3, and 5. (C) Cell area quantification of osteoporotic osteoblasts from different groups on day 5. (D) qRT-PCR analysis for ATP2A2 and FGF23 gene expressions of osteoporotic osteoblasts from different groups on day 5. (E) Western blotting analysis for ATP2A2 and FGF23 protein expressions of osteoporotic osteoblasts from different groups on day 5; All data are reported as mean ± standard error. ANOVA with Tukey's post hoc test
2). FGF23 alleviates neuronal apoptosis and inflammation, and promotes locomotion recovery via activation of PI3K/AKT signalling in spinal cord injury. Experimental and Therapeutic Medicine, 2023 (PubMed: 37383378) [IF=2.7]

Application: WB    Species: Rat    Sample:

Figure 1 Cell apoptosis, FGF23 and PI3K/AKT signalling in H2O2-stimulated primary neurons. (A) Relative mRNA expression levels, (B) representative western blotting images of FGF23 and (C) FGF23/GAPDH level. (D) Semi-quantification of apoptotic rates and (E) representative flow cytometry plots of Annexin V/PI staining. (F) Representative western blotting images and (G) relative protein expression levels of C-caspase3 and Bcl-2. (H) Representative western blotting images and (I) relative expression ratios of p-PI3K/PI3K and p-AKT/AKT. GAPDH was used as a loading control. *P
3). IL-6, IL-1β and TNF-α regulation of the chondrocyte phenotype: a possible mechanism of haemophilic cartilage destruction. Hematology (Amsterdam, Netherlands), 2023 (PubMed: 36799502) [IF=1.9]

Application: WB    Species: Human    Sample: chondrocytes

Figure 2. IL-6, TNF-α and IL-1β upregulated FGF23 and downregulated SOX9 protein expression in HUM-iCell-s018 chondrocyte cells. Chondrocytes were treated with gradient concentrations of IL-6, TNF-α or IL-1β (0, 1, 5, 10 ng/ml) for 24 h and protein expression of FGF23 and SOX9 in chondrocytes was determined by WB (a – e). Data are expressed with mean ± SD; (b – e) *p 

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.